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Introduction 
 
“Our immune system is the body’s sixty sense”. It is faced with the daunting 
job of defending the organism against invading pathogens, while at the same 
time maintaining tolerance to body’s own tissues, thereby preserving its 
integrity1. At the completion of development, T and B cells emerge from the 
primary lymphoid organs and enter the re-circulating pool of peripheral 
lymphocytes. One of the first things these naïve cells encounter in their fully 
mature state are antigens from various non-lymphoid organs that were 
thought to be restricted in their expression to a particular peripheral tissue. 
Several mechanisms act together to ensure self-tolerance2, including clonal 
deletion, anergy, ignorance and exhaustion, effector T-cell and regulatory T-
cell balance, and cytokine deviation. An imbalance between pro-
inflammatory and anti-inflammatory cytokines, autoreactive and 
inflammatory T helper 1 (Th1) cells, and regulatory T cells results in the 
loss of immune tolerance, the breakdown of immune homeostasis and the 
subsequent appearance of exacerbated inflammatory conditions and 
autoimmune disease3. 
 
Immunological tolerance  
The “central lymphoid tissues”, which are bone marrow for B cells and 
the thymus for T cells, are the site of the V(D)J recombination, the process 
of unique B cell receptor (BCR) and T cell receptor (TCR) genes assembly 
from three separate gene segments, the variable (V), diversity (D) and 
joining (J) genes, during B and T-cell differentiation. In addition, during 
each immune response, somatic hypermutation substitutes single 
nucleotides of BCR genes in peripheral lymphoid tissues (such as the 
spleen, lymph nodes and tonsils). A significant fraction of the receptors 
generated by both these processes bind to one or more self-components in 
the body by-product of a deliberately random receptor-generating process4. 
Between 20 and 50% of TCRs and BCRs generated by V(D)J recombination 
bind with a potentially dangerous affinity to a self antigen5. Since only 3–
8% of the population develops an autoimmune disease6, it is remarkable that 
this enormous burden of self-reactive receptors is so well regulated. 
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Each lymphocyte usually produces only a single receptor out of the 
billions possible. Experiments have established that if this receptor is self 
reactive, then four cellular strategies are employed to deal with it (Figure 
1). First, the cell displaying the “forbidden”, or self-reactive, receptor can be 
triggered to die, as originally envisaged in Burnet’s concept of clonal 
deletion. Second, a cell bearing a forbidden receptor can “edit” it by further 
V(D)J recombination or somatic hypermutation to display a different 
receptor that is not self reactive. Third, intrinsic biochemical and gene-
expression changes can reduce the ability of the cell to be triggered by self-
reactive receptors. This is generally termed clonal anergy or tuning7. 
Finally, even if the cells have evaded the three mechanisms above, 
collectively called “immunological ignorance”, extrinsic controls can limit 
the danger of self-reactive receptors. These extrinsic controls limit the 
supply of essential growth factors, costimuli, pro-inflammatory mediators 
and other factors, and also include active suppression by regulatory T (Treg) 
cells, through a mechanism that is poorly understood.  
 
 
     
 Christopher C. et al. Nature. 2005. 435, 590-597. 
 
Figure 1. Four cellular strategies are used to regulate self-reactive receptors at different points 
during B- and T-cell differentiation. a) The cell is deleted through induction of cell death. b) The 
receptor is edited to one that is less self-reactive. c) Biochemical or gene-expression changes 
intrinsically dampen the self-reactive receptor’s ability to activate the cell. d) The ability of self-
reactive cells or antibody to cause autoimmunity is limited by using extrinsic suppression and by 
limiting essential growth factors, costimuli and inflammatory mediators. 
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The coexistence of autoreactive and protective T cells was revealed by 
the multi-organ autoimmunity observed in lymphopenic (immune-deficient) 
recipient mice upon adoptive transfer of naïve CD4+ T cells, and by the 
protection from autoimmune pathology upon co-transfer of a subset of 
CD4+ T cells expressing interleukin (IL)-2 receptor alpha-chain (CD25)8. 
Current evidence suggests that the CD25+CD4+ T cells could be themselves 
self reactive (Figure 2), and that this property plays an essential role in the 
commitment to a Treg-cell lineage. An essential function for TCR signals in  
the development of Treg cells was suggested by the finding that TCR-
transgenic mice on a recombination-activating gene-deficient background 
(which lack endogenous TCR rearrangements) do not develop Treg cells, 
whereas most TCR-transgenic mice expressing functional recombination-
activating genes contain varying numbers of Treg cells9. Thus, self-
reactivity can be beneficial as part of a dedicated cellular mechanism 
preventing autoimmunity. 
In addition to CD25+CD4+ Treg cells, other important self-reactive T cell 
sub-lineages have been identified. Prominent among these are cells that 
express a semi-invariant T-cell receptor (TCR) specific for conserved self-
ligands (Figure 2). These ligands, which are normally present at a low level, 
might be induced and serve as molecular signs of stress or infection. The 
best characterized such T-cell sub-lineage is the CD1d-dependent Natural 
Killer T cell (NKT)10. 
 
 
 
 Kronenberg M. & Rudensky A. Nature. 2005. 435, 598-604.  
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Figure 2. Recognition of self-agonist ligands in the thymus can create at least two different 
sublineages of self-reactive T cells. They probably branch off from the mainstream pathway of 
development at the double positive stage of differentiation. Thymic TR precursors can also branch off 
at the CD4 single positive stage of differentiation. MHC class II+ bone-marrow derived cells may 
also participate in TR-cell selection. TEC, thymic epithelial cell. Vx, diverse Vregions. 
 
Treg population is able to regulate the immune responses to 
autoantigens, tissue transplant, allergens and microbial pathogens8. Despite 
the first observation on Treg was published on 1995 by Sakaguchi et al.11, a 
complete functional characterization of these cells is still lacking. Treg cells 
are able to control the effector cells in terms of clonal expansion, 
differentiation, cytokine profile and tissue migration during immune 
response. Recent in vivo observations12 have been suggesting that Treg 
activity occurs at level of T cell-Dendritic Cells (DC) interaction during the 
antigen-priming phase. It is relevant that Treg control T cell priming in 
lymphoid organs but are also able to inhibit immune response in peripheral 
tissues13. Intriguingly, the removal of Treg significantly enhances NK cell-
mediated bone marrow rejection in murine models. 
NKT cell subset, in humans, preferentially expresses an invariant 
Valpha24+Jalpha18+Vbeta11+ TCR (NKTi). NKTi are activated by alpha-
galatoctosylceramide with a CD1d-restricted pattern10. Recent reports 
indicate that NKTi cells can be subdivided in CD4+CD8- and CD4-CD8- 
subsets, diverging in their ability to target CD4+T cells, NK and B 
lymphocytes, and CD8+ T cells, respectively14. NKTi cells produce a variety 
of immune-regulatory cytokines ascribing either to pro-inflammatory T 
helper 1 (IFN-gamma and TNF-alpha) and/or to anti-inflammatory T helper 
2 (IL-10 and IL-4) profile15. As recently reviewed, this paradoxical behavior 
renders difficult to predict the functional consequences of NKTi activation 
in immune regulation in vivo16. Indeed, NKTi cells can exert anti-tumor 
cytotoxicity and anti-proliferative activity17,18. Intrigue, tumor immune 
surveillance by NKTi can be also detrimental15.  
 
Why does autoimmunity develop in about 5% of people? 
Autoimmune diseases arise when the immune system turns its 
antimicrobial defenses upon normal components of the body such as 
insulin-producing pancreatic cells in Type 1 diabetes or chromatin in 
systemic lupus erythematosus (SLE). Immunologists identified a number of 
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specific genes and cellular mechanisms involved in immunological self-
tolerance that, when disrupted by inherited mutations, cause autoimmune 
disease. Despite complete failure of individual tolerance mechanisms, these 
autoimmune diseases have a delayed stochastic penetrance19. 
Major Histocompatibility Complex (MHC), namely Human Leukocyte 
Antigens (HLA) in humans, represents a major susceptibility factors for the 
development of autoimmune diseases in humans. The MHC, or HLA,  
consists of a set of polymorphic genes encoding both class I and class II 
glycoproteins. The main biological role of such molecules is to bind 
antigenic peptides and present them to T cell scrutiny. Moreover, MHC 
polymorphism tends to concentrate in hypervariable regions20, 
corresponding to MHC binding pockets engaging specific anchor residues 
of their peptide ligands. This pattern of variation in HLA molecules is 
different from that in most other protein-coding genes, in which allelic 
variation tends to occur more in introns than in exons21. 
HLA are unequivocally involved in several autoimmune diseases. 
However, the mechanism by which HLA genes contribute to disease 
development in humans is still largely unknown. One exception is Celiac 
Disease, whereby a mechanism through which HLA molecules contribute to 
the disease has now been unraveled by carefully analyzing T cells from the 
lesions22. HLA genes are crucial for antigen presentation to T lymphocytes 
and for activation of NK cells. Moreover, HLA genomic region contains 
many other genes with putative or proven immune functions.23   
 
 Bone marrow failure, hematopoietic clonal expansion and 
autoimmunity 
Bone marrow (BM) failure syndromes are very illustrative with 
regard to pathophysiology of the stem cell compartment, its physiologic and 
pathophysiologic regulation as well as mechanisms of clonal evolution24. 
Stem cell impairment may be primary or secondary when due to systemic 
diseases or iatrogenic causes. A quantitative defect of stem cells has been 
documented in Aplastic Anemia (AA), Paroxysmal Nocturnal 
Hemoglobinuria (PNH) and Myelodysplastic Syndromes (MDS) as 
measured by flow cytometry of CD34+ cells, colony-forming cells as well as 
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long-term culture initiating cells, the most immature in vitro equivalents of 
hematopoietic stem cells25,26. In most cases of BM failure an immune-
mediated attack against haemopoietic progenitors and/or mesenchimal 
elements has been hypothesized . Although AA is the prototype of primary 
hematopoietic stem cell failure27,28depletion or functional deficiency of stem 
cells also occurs in MDS and PNH. A great number of evidence point 
towards an immune-mediated inhibition of hematopoiesis in these 
pathologies at specific differentiation stages, but the efficacy of immune-
suppressive strategies targeting T cells support the hypothesis of the 
involvement of T cells in the pathophysiology of a great number of bone 
marrow failure syndromes. Clearly, some forms of immune cytopenias, such 
as those seen with SLE, and autoimmune neutropenia, are mediated by 
antibodies likely directed against early or more mature hematopoietic 
progenitor cells. Theoretically, even if T cells are mostly responsible for the 
damage to the progenitor and stem cell compartment, one could speculate 
that the cellular immune response will be accompanied by a corresponding 
antibody production29. Depletion of stem cell compartment could be due to 
an autoimmune attack by T lymphocytes and to the damage exerted by 
inhibitory cytokines, products of activated immune cells. Effector 
mechanisms in hematopoietic inhibition may involve various pathways, 
including release of inhibitory cytokines leading to apoptosis of 
hematopoietic progenitor and stem cells. The specificity of such a 
mechanism may be difficult to reconcile with a sometimes very narrow 
spectrum of hematopoietic inhibition as seen in single lineage cytopenias. 
Direct perforin/granzyme-mediated killing by cytotoxic effector cells may 
be another mechanism by which specific targeting of stem cells or 
progenitors can be explained. Clearly, the distribution of target antigens 
may determine the killing spectrum. Terminal differentiated citotoxic 
lymphocytes (CTL) are likely the most efficient effector cells and so far 
there is little evidence that the hematopoietic inhibition can be mediated by 
natural killer cells. It is possible that a CTL population lacking CD28 and 
expressing CD57 contains most of the pathogenic clones and can serve as a 
source of T cells for molecular TCR analysis29. 
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The possibility that these processes could be of critical relevance to 
favor the emergence of hemopoietic clones, able to escape immune 
aggression via different mechanisms, is a consistent work hypothesis.  
Several theories can be put forward to explain the initial steps in the 
evolution of clonal stem cell diseases such as MDS. Contraction of the stem 
cell compartment may result in a ‘benign clonality’ of hematopoiesis. For 
example, in AA blood cells may be clonal or oligoclonal as a result of very 
few stem cells contributing to blood production; polyclonal hematopoiesis is 
restored upon successful therapy. Observation of the disappearance of clonal 
abnormalities following successful immunosuppressive therapy and 
restoration of polyclonal hematopoiesis also supports the notion that clonal 
outgrowth may be a result of decreased numbers of operative normal 
hematopoietic clones. In contrast, acquisition of a genetic defect by an 
individual stem cell resulting in clonal expansion may be the primary event 
leading to the gradual dis-replacement of normal hematopoiesis24.  
 
 
Paroxysmal Nocturnal Hemoglobinuria 
 
PNH is a hematological syndrome characterized by the emergence of a 
hematopoietic progenitor bearing somatic mutations in the 
phosphatidylinositolglycan-A (PIG-A) gene. The protein encoded by this gene is 
essential for the synthesis of the glycosylphosphatidylinositol (GPI) anchor30,31. 
Given that the PIG-A mutation in PNH patients occurs in a hematopoietic stem cell, 
a defective clonal hematopoieis, together with a residual polyclonal hematopoieis, 
develops through several lineages and accounts for the mixed (GPI+ and GPI-) 
phenotype, commonly present in peripheral blood of PNH patients32,33. From the 
clinical point of view, a triad of hemolytic anemia, venous thrombosis and blood 
cytopenias characterizes PNH. The most dramatic consequences are seen in red 
blood cells, where two of GPI-linked proteins, CD55 (decay accelerating factor, 
DAF), and CD59 (membrane inhibitor of reactive lysis, MIRL), are responsible for 
controlling the activity of plasma complement34. The Coombs-negative, intravascular 
hemolysis (and the resultant hemoglobinuria), that are the clinical hallmarks of 
classic PNH, are attributable to deficiency of CD55 and CD59 because peripheral 
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blood erythrocytes derived from the mutant clone lack the capacity to restrict cell-
surface activation of the alternative pathway of complement35.  
Clinical data have indicated for a long time a close link between PNH and aplastic 
anemia, and there is much circumstantial evidence implicating an autoimmune 
mechanism for the development of aplastic anemia36. By extrapolation, this could 
apply to PNH as well. Infact, it has been hypothesized that the expansion of the PIG-
A negative clone is the consequence of a somatic cell selection resulting from the 
presence of autoreactive T-cells directed against GPI-anchored proteins in the 
context of MHC and MHC-like molecule on the surface of hematopoietic stem 
cell37,38. Consistently, a T-cell receptor Vβ-chain skewing has been described in 
PNH, suggesting a T-cell mediated process leading to suppression of hematopoietic 
function39. Recent evidence points to a pathogenic role of specific subsets of 
cytotoxic cells, particularly T40, NK and NKT cells41,42. In PNH patients, in vitro 
assays for BM colony-forming cells have shown that PNH cells are less sensitive to 
interferon-gamma (IFNγ) and to TNFα43. New relevant data have emerged from 
RNA microarray analysis of CD34+ hematopoietic progenitors: amongst these, GPI+ 
cells, compared with GPI- cells, had an increased expression of pro-apoptotic 
genes44. In addition, when normal CD34+ cells were exposed to IFN- γ this produced 
changes in the gene expression profile similar to those seen in GPI+ cells from PNH 
patients45, suggesting that the latter individuals were suffering from exposure to IFN-
γ (Figure 3). 
 
 
 
                 C.J. Parker.Experimental Hematology . 2007. 35, 523–533 
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Figure 3. Model of two-step hypothesis of PNH pathophysiology. Upper panel: Hematopoietic 
stems cells and primitive progenitors with mutant PIGA are present in normal marrow, but they are 
not apparent because no selection pressure has been applied and they have no intrinsic 
growth/survival advantage. Middle panel: In the setting of immune-mediated bone marrow injury, 
PIGA mutant cells are selected because they have a growth/survival advantage based on GPI-AP-
deficient phenotype. Additional PIGA mutant HSC are produced as a consequence of this process 
because the mutational frequency of the gene is enhanced by stress erythropoiesis. Lower panel: 
Clonal expansion is the result of genetic or epigenetic events that activate genes that work in concert 
with mutant PIGA, GPI-AP deficiency to enhance further the proliferative advantage of the mutant 
cells. Under these conditions, PNH has the characteristics of a benign clonal myelopathy.    
 
 
Myelodysplastic Syndrome  
Myelodysplastic Syndromes (MDS) are clonal disorders 
characterized by an ineffective hematopoiesis followed by frequent 
development of Acute Myeloid Leukemia (AML). Cytopenia, accompanied 
by a bone marrow, generally hyper-cellular, exhibiting dysplastic changes, 
represents the hallmark of MDS46. Etiological factors of MDS are largely 
unknown; most cases are idiopathic (de novo MDS). The onset of idiopathic 
MDS depends on a complex sequence of events; several factors, such as 
antineoplastic alkylating agents, ionizing radiation, and benzene, were 
shown to have a clear association and etiological factors for secondary 
MDS. A great number of evidence proposed immune-suppression of 
progenitor cells growth with accelerated rate of apoptotic cell death. In this 
context, the emergent MDS clones acquire resistance to apoptosis induction, 
allowing them to proliferate without undergoing immune-selection. 
Successive, progressive genetic changes have been suggested to account for 
the leukemic transformation of MDS cells47. (Figure 4) 
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Figure 4 MDS constitute a complex range of stem-cell diseases. The myelodysplastic syndromes 
(MDS) cell clone can suppress normal hematopoiesis (a) directly or indirectly through stroma. Stem-
cell defects can result in singlelineage deficiency (refractory anaemia and ringed sideroblasts (RARS; 
b)) or multiple-lineage deficiencies (refractory anemia with excess blasts (RAEB; c)). MDS stem-cell 
diseases (d) might seem like de novo acute myeloid leukemia (AML), however, the two are 
distinguishable. For example (e), cytopenias in de novo AML can be more restricted owing to a 
failure in differentiation. HSC, hematopoietic stem cell. 
 
The evaluation of disease risk and outcome of patients with MDS is a 
critical point. In this context, multiple parameters like chromosomal 
changes, bone marrow blast cells number and the presence of multiple 
cytopenia appear to be useful in predicting the survival and transformation 
rate in MDS patients48. There are a number of disparate methods to evaluate 
the potential clinical outcomes for patients with MDS. Original assessment 
of prognostic factors has been suggested by the French–American– British 
Morphology group (FAB) in 198249 and, following that, at least six 
additional risk classification systems have been developed to predict 
survival and/or evolution to AML. In 1997, the International MDS Risk 
Analysis Workshop proposed the International Prognostic Scoring System 
(IPSS), which has compared favorably with the previous most widely used 
MDS risk evaluation systems48. According to IPPS, MDS patients can be 
classified into distinct prognostic subgroups based on medullary blast cell 
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count, number of cytopenias, and clonal chromosomal abnormalities. Based 
on these variables, four risk subgroups regarding survival and AML 
evolution were suggested: low-risk, 0; intermediate-1 risk (INT-1), 0.5–1.0; 
intermediate-2 risk (INT-2), 1.5–2.0; and high-risk, ≥2.5, with a median 
survival ranging from 5.7 years for low-risk MDS patients to 0.4 years in 
high-risk patients50,51. 
One of the paradoxes present in MDS is the presence of peripheral 
cytopenias and a hypercellular BM. All of the models suggest that the 
development of MDS might be due to a multi-step process that originates in 
the earliest progenitor cell, a pluripotent stem cell52. The initial assault or 
mutation occurs in the DNA of this cell, which adversely affects its 
differentiation and maturation. Three epidemiological studies have 
suggested that environmental factors (radiation, smoking, pesticides, 
organic solvents, heavy metals) contribute to the development of de novo 
MDS53,54,55. Recently, it has been hypothesized the relevance of immune-
mediate pathway in stem cells depletion. The damaged cell, the clone, 
achieves a proliferation advantage that results in ineffective hematopoiesis. 
Apoptotic agents such as tumor necrosis factor-alpha (TNF-α), Fas/Fas-
ligand, and a relative deficiency in hematopoietic growth factors result in 
the premature death of BM cells, and disease progression is associated with 
diminished immune response and a loss of tumor suppressor activity52. 
The clonal nature of MDS was confirmed by various techniques56,57. The 
abnormal clone can lead to an increase in cell proliferation in all 
hematopoietic cell lineages, but especially in the myeloid cell lineage58. 
However, the increased proliferation rate of the clonal population in the 
bone marrow is quickly equilibrated by an increase in apoptosis56,58,59. The 
clonal cells do not mature or differentiate and the majority of them remain 
in the BM. As a result, despite the high proliferation activity in the BM, the 
patient suffers from peripheral cytopenia. The majority of studies 
demonstrated that increased apoptosis, observed in patients with MDS 
compared to normal controls, was more pronounced in early stages of MDS 
than in advanced stages, and was largely restricted to CD34-positive 
cells60,61. Excessive cell death was largely restricted to the early MDS 
subtypes. Progression to AML was accompanied by a reduction in both 
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apoptosis and proliferation rates and may suggest that progression to AML 
is associated with a decreased susceptibility to apoptosis61. However, earlier 
data by Raza et al.58 is in direct conflict with this, contending that apoptosis 
was maximal in advanced MDS and was restricted to more differentiated 
CD34-negative cells. As will be further discussed below, a T-cell attack on 
haemopoietic cells has been documented in MDS patients62. The ‘T against 
the Clone’ scenario includes an immune reaction operated by T cells, which 
in early stage MDS creates an apoptotic environment by the release of 
inhibitory cytokines and up-regulation of Fas expression on hemopoietic 
progenitors.  
The acquisition of secondary genetic events is a model proposed to 
explain the stepwise progression of MDS to acute leukemia. These yet 
unrecognized epigenetic hits possibly perturb apoptotic cell-signal 
transduction pathways of the primitive clone, altering its apoptotic nature 
and offering it a growth or survival advantage. Alternatively, excessive 
apoptosis in early stage MDS could be interpreted as an immune response to 
antigens expressed by the clonal aberrant cells. This process probably delays 
the leukemic evolution, but also leads to BM failure. As the disease 
progresses immune reactions become ineffective in controlling the 
accumulatively damaged myeloid clone, thus allowing its expansion. 
Studies reporting increased Fas susceptibility and apoptosis of MDS cells 
with trisomy 8, but not with monosomy 7, support this perception63,64. In 
contrast, the autologous immune response against leukemic clones in 
patients with AML and chronic myeloid leukemia is less evident. The 
reasons for this failure include: insufficient antigen presentation by the 
malignant cells, immune suppression by soluble or cellular factor(s), and an 
insufficient number of specific lymphoid cells to react with the rapidly 
growing clone. (Figure 5) 
 15
 
 
Figure 5. Pathogenesis model of MDS. A great number of mechanisms, causing the defective 
hematopoiesis and the expansion of dysplastic clones, have been proposed. The initial assault or 
mutation occurs in the DNA of hematopoietic stem cell, which adversely affects its differentiation 
and maturation. Environmental factors contribute to the development of de novo MDS. The damaged 
cell, the clone, achieves a proliferation advantage that results in ineffective hematopoiesis. In 
addition, selective pressure by effector cells could inhibit polyclonal hematopoiesis, favoring the 
selection/shaping of dysplastic clones.  Moreover, mechanisms of gene silencing and oncogene 
activation could favor the neoplastic progression.  
 
It is worth noting that a number of data refer significant increase of Treg 
cells in cancer patients65. This evidence suggests a deleterious role for Treg 
in suppressing the immune response against cancer as well as the ability of 
certain tumors to recruit or to expand Treg66. In this regard, some 
observations indicate that this increased frequency is due to active 
proliferation rather than redistribution from other compartments67, while 
attraction of Treg cells via CCL22/CCR468, and their induction by 
Prostglandin E2 or H-ferritin have been proposed. Studies on Treg in 
hematological tumors are far to be complete. The presence of increased 
Treg cells has referred in Hodgkin Disease, in Chronic Lymphocytic 
Leukemia and in Multiple Myeloma patients65. Some of these studies need 
to be validated by using specific markers such FoxP3. Largely unknown 
appears the analysis of other regulatory populations like NKTi cells in 
hematological tumors as well as in non malignant haemopoietic disorders. 
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Aim of the study 
  
This work got inside the biological mechanisms underlying the ongoing 
relationships between an expanding hematopoietic clone and the immune 
effectors seeding the BM. In this context, the study analyzed two 
hematological disorders, showing different clinical manifestations, in which 
defective or dysplastic clonal hematopoiesis develops through several 
lineages and replaces the normal counterpart (PNH and MDS). This clinical 
feature, suggesting an active BM failure condition, is expected to provide a 
useful model to investigate the potential involvement of T cell-mediated 
processes in pathogenesis of these two hematopoietic disorders. 
 
In order to investigate whether an absolute growth vantage might 
underlie the expansion of GPI-defective compartments, in the first phase of 
the work the immune response in PNH patients has been characterized, with 
particular attention to functional differences between normal (GPI+) and 
GPI-defective compartments. Then, the relevance of an altered regulation of 
immunological tolerance in the clonal emergence and expansion of GPI-
defective clone has been investigated.  
To this aim, the this part of the study addressed:  
a) Functional analysis of innate and adaptive immune response in PNH 
patients: 
? Study of normal (GPI+) and GPI-defective granulocyte cell 
compartments and their ability of bacterial-dependent intracellular 
ingestion with the consequent activation of oxidative burst. 
? Study of normal (GPI+) and GPI-defective monocytes cell 
compartments and their ability to differentiate in vitro into functional 
Dendritic Cells (DC); 
? Characterization of (GPI+) and GPI-defective T cells compartments: 
b) Analysis of immunological tolerance regulation in PNH: Study of CD40-
pathway 
c) Analysis of a major susceptibility factor for autoimmunity:  HLA class I and 
II genes; 
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The second part of the study has been investigated the biological mechanisms 
underlying the tolerance control and immune-dependent shaping of 
emerging/dominant clones in the BM of MDS patients. Thus, the correlation 
between the presence of a hyper-cellular, hypo-cellular BM environment, the 
stage of MDS progression and the immunological asset along MDS progression 
to AML, has been investigated. 
 
 This part of the study addressed: 
a) Analysis of BM and peripheral blood immunological asset of MDS patients at 
different disease stages. 
b) Analysis of BM recruitment of Treg and NKTi lymphocyte subsets in MDS 
patients along AML progression, as compared with healthy controls. 
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Methods 
 
Patients and controls 
Patient enrolment, classification and clinical management have been 
performed at the Division of Hematology, Department of Biochemistry and 
Medical Biotechnology of the University of Napoli “Federico II”. BM and 
peripheral blood sample collection, karyotype analysis, chromosome and 
cytogenetic characterization of MDS patients have been performed at the 
same Institution. PNH diagnosis has been documented in all cases by flow 
cytometry analysis of peripheral blood, using labeled monoclonal antibodies 
(mAb) against GPI-linked molecules, as described69,70.  Notably, the 
Division of Hematology represents one of the National Reference Centers 
for PNH, a very rare syndrome. MDS patient’s clinical classification has 
been performed according to the WHO recommendations71. The stage of the 
disease has been evaluated following the IPSS criteria. None of the enrolled 
patients was receiving any medical treatment along the study. Informed 
consent has been obtained from individual patients before each blood 
sample collection. A group sex- and age-matched healthy donors were used 
as controls. 
 
mAb, immunofluorescence, and flow cytometry 
Fluorescein isothiocyanate (FITC), phycoerythrin (PE), cychrome, and 
allophycocyanin-labeled mAb against CD3, CD4, CD8, CD56, CD25, 
CD45, CD48, CD54, CD19, CD33, CD66b, CD14, human leukocyte 
antigen (HLA)-DR, CD154, interferon-gamma (IFN- γ), interleukin (IL)-4, 
TCRVα24Vβ11 and isotype-matched controls have been purchased from 
BD PharMingen (San Jose, CA). The PE-labeled CD48 mAb has been 
purchased from Serotec Ltd.(London, UK). The PE-labeled anti-human 
FoxP3 kit has been purchased from EBioscience (San Diego, USA) and 
used according to manufacturer’s instruction. To analyze the production of 
IFN- γ and IL-4, intracellular staining with the specific mAb has been 
performed by using the fixing/permeabilization kit purchased from Caltag 
(Burlingame, CA) following the manufacturer’s instructions. All phenotypes 
referred to flow cytometry analysis of the cell populations gated by using 
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forward-scatter and side-scatter parameters, as well as CD45 labeling. Flow 
cytometry, acquisition and data analysis have been performed by using a 
two-laser-equipped FACSCalibur apparatus and the CellQuest analysis 
software (Becton Dickinson, San Jose, CA). 
 
PBMC, DC and resting T cell populations 
Peripheral blood mononuclear cells (PBMC) have been isolated from 
patients and controls by centrifugation of peripheral blood over 
Lymphoprep (Nycomed, Oslo, Norway) gradient. To obtain a purified 
monocyte population, the cells collected from the plasma/Lymphoprep 
interface have been washed phosphate buffer saline (PBS) and incubated at 
37°C in the presence of RPMI-1640 medium (Gibco-BRL, Grand Island, 
NY) in six-well plates (Falcon, Seattle,WA). After a 2-h incubation, the 
non-adherent cells have been removed, and each well has been washed three 
times with PBS. Adherent cells were cultured for a 7-day period in the 
presence of 80 ng/ml human recombinant granulocyte macrophage-colony 
stimulating factor (hrGM-CSF) and 1000 IU/ml hrIL-4 (Sigma-Aldrich), as 
described66. When indicated, lipopolysaccharide (LPS; 100 ng/ml, Sigma-
Aldrich) or human trimeric CD40 ligand (CD40L) molecule (100 ng/ml, 
Bender MedSystems, Austria) has been added to the culture for an 
additional 16–24 h to induce terminal DC differentiation72. The purity of the 
DC population has been defined by immune fluorescence phenotype 
analysis. Only the populations showing less than 5% of lymphocyte 
contaminants have been used in the study. The ability of these DC 
populations to elicit antigen dependent T cell proliferation has been assessed 
by incubating DC with 10 μg/ml purified protein derivative (PPD; Staten 
Serum Institute, Copenhagen, Denmark) for 2 h at 37°C. After extensive 
washing, PPD-treated DC have been 30 Gy-irradiated and cultured for 5 
days in the presence of autologous PBMC.  
T lymphocytes were isolated from venous peripheral blood samples 
obtained from healthy controls as described previously73. Briefly, small, 
resting T cells have been purified from the PBMC population using a 
Percoll density gradient, after removing B cells and monocytes by plastic 
and nylon wool adherence. The recovered high buoyant density population 
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was always >97% CD3+CD56–. Purity of T cell preparation has been 
assessed using immunofluorescence and phytohemaglutinin stimulation.  
 
Study of Phagocytosis: Analysis of Granulocyte Bacterial Ingestion and 
Respiratory Burst Induction  
To study the phagocytic process in GPI-defective polymorphonuclear 
cells (PMN) of PNH patients, their effectiveness in ingesting opsonized 
bacterial particles by using FITC-labeled E. coli previously treated with 
human IgG immunoglobulins, as well as with serum- derived complement 
have been measured. Their specific bacterial intracellular ingestion has been 
measured as mean fluorescence intensity (MFI) in the green channel of the 
FSC–SSC gated PMN population, by using flow cytometry analysis. The 
evaluation has been performed after incubation at 37°C of the whole blood 
in the presence of the bacterial stimuli (1x109 bacteria/ ml), as indicated in 
the Result section. The use of a staining DNA solution allowed the 
identification of the diploid PMN population and the simultaneous exclusion 
of artifacts dependent on bacteria aggregates. To discriminate between 
attachment and ingestion of labeled bacteria, an appropriate quenching 
solution has been applied after the 37°C incubation of the whole blood. The 
percentage of granulocytes having performed phagocytosis has been 
detected on the FSC/SSC-defined region gate, also considering the DNA 
diploid content, as represented by the red fluorescence level of the PMN 
population74. To perform the kinetic analysis, the blood samples have been 
immediately put on ice after each incubation and erythrocytes have been 
removed by osmotic lysis. All the reagents have been purchased as 
Phagotest kit, from Orpegen Pharma, Heidelberg, Germany and used 
following the manufacturer’s instructions. 
The quantitative detection of PMN oxidative burst has been performed in 
heparinized whole blood samples by using the Phagoburst kit, purchased 
from Orpegen Pharma, and following the manufacturer’s instructions. 
To activate the respiratory burst, whole blood samples pretreated with the 
DHR 123 radical oxidant sensitive probe were incubated with the opsonized 
E. coli (1x109/ml), fMLP (5 mM), and phorbol 12-myristate 13-acetate 
(PMA, 8 mM) at 37°C, as indicated in the Result section. After the 
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activation with the above stimuli, samples were kept on ice, erythrocytes 
have been lysed and DNA staining solution added to identify the diploid 
PMN population and exclude aggregation-dependent artifacts. The 
percentage of granulocytes having performed the oxidative burst has been 
detected on the FSC/SSC-defined gate, also considering the DNA diploid 
content, as represented by the red fluorescence level of the PMN population. 
The quantitative assessment of the respiratory burst has been performed as a 
measure of the DHR 123 intracellular oxidation (MFI in the green emission 
channel of the PMN population). The effect of the PKC inhibitor 
bisindolylmaleimide (BDM), purchased from Sigma-Aldrich, St Louis, MO, 
on E. coli-triggered phagocytosis and Reacting Oxygen Species (ROS) 
production by PMN was also analyzed. Briefly, after a pretreatment of 30 
min in the presence of 100 nM BDM, opsonized E. coli (1x109/ml) has been 
added for an additional 10 min incubation period. Bacteria uptake and ROS 
detection has been performed as previously described. These conditions 
have been described to allow specific PKC activity inhibition and were 
observed to completely block PMA-triggered PMN respiratory induction. 
No significant effects on PMN viability have been observed by Trypan blue 
and propidium iodide staining. 
 
Analysis of lymphocyte proliferation 
PBMC (1x106/ml) were cultured in 24 or 96 well, flat-bottomed plates 
(Falcon) with anti-CD3 mAb CLB-CD3/E (immunoglobulin E), a gift of Dr. 
R. van Lier (Central Laboratory of the Blood Transfusion Service, 
Amsterdam), phorbol 12-myristate 13-acetate (PMA), and ionomycin, all 
purchased from Sigma- Aldrich Italia (Milan). Cultures have been incubated 
for 3–5 days at 37°C in a humidified atmosphere containing 5% CO2 and 
pulsed with 0.5 μCi/well [3H] thymidine for the last 16 h. The incorporation 
of the labeled nucleotide has been determined by scintillation counting after 
automatic cell harvesting. All tests have been performed in the presence of 
RPMI-1640 medium supplemented with 5% heat-inactivated fetal calf 
serum (Gibco-BRL). Autologous serum was used for antigen-specific 
assays. 
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To analyze the proliferation of GPI+ and GPI– T lymphocytes, PBMC have 
been labeled with 5, 6-carboxyfluorescein-diacetate-succinimidyl ester 
(CFSE; Molecular Probes, Eugene, OR) before the culture with the anti-
CD3 CLB-CD3/E mAb. This technique has been described already as a 
reliable replacement of 3H thymidine incorporation for the evaluation of 
lymphocyte proliferation75. 
Indeed, CFSE fluorochrome spontaneously and irreversibly couples to 
intracellular proteins and is equally distributed to the daughter cells after 
mitosis. Proliferating cells can be tracked by flow cytometry, based on the 
sequential loss of fluorescence intensity. Furthermore, multi-parametric 
flow cytometry analysis allows the simultaneous assessment of normal and 
GPI-defective T cell subsets within the dividing cell population, also 
monitoring their phenotype changes associated with activation and cell 
division. All tests have been performed in the presence of RPMI-1640 
medium supplemented with 5% heat-inactivated fetal calf serum (Gibco, 
Grand Island, NY). 
 
Typing techniques 
Low and high resolution typing for HLA-A, -B, -Cw and -DRB1 genes has 
been carried out by polymerase chain reaction with sequence specific 
primers (PCR-SSP). Commercial kits from Dynal A.S. (Oslo, Norway) have 
been used according to the manufacturer’s instruction.  
 
Statistical analysis 
The statistical analysis for P calculation has been performed by using 
Student’s t-test. Results have been considered significant when a P value < 
0.05 was obtained. HLA Association has been tested by two-tailed Fisher’s 
exact test with software InStat 3.0 (GraphPad Software Inc., San Diego, 
California, USA). For typing tests, the corrected p value (pc) were 
calculated by multiplying the p value by the number of the alleles showing 
at each locus a frequency > 0.5% in Italians.76,77 (i.e.14 alleles at A locus 
with 3 specificities for A*02, 21 at B locus with 2 specificities for B*14, 13  
at C locus with 2 specificities for Cw*08, 12 at DRB1 locus with  2 
specificities for DRB1*01 and 3 for DRB1*15) (Table I).  
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Results 
 
Study of GPI-defective compartment in PNH: GPI-defective 
granulocytes from PNH patients show significant increased ingestion 
effectiveness and a decreased oxidative burst induction. 
To analyze the GPI-defective granulocyte effectiveness, we focused on 
their ability to ingest corpuscolate bacteria by using fluorescein- labeled 
opsonized E.coli bacteria. To avoid a possible interference of the isolation 
procedures on granulocyte activity, we selected for the study PNH patients 
whose percentage of GPI-defective PMN was > 95% . As shown in Figure 
6, GPI-defective granulocytes from PNH patients exhibit a significant 
increase in their ability to ingest opsonized E. coli bacteria. 
 
 
Figure 6. Bacterial ingestion in PNH GPI-defective granulocytes. Panel A shows the E. coli uptake 
levels in one representative experiment. Bold and light lines indicate staining profiles of PNH and 
normal PMN, respectively, after 20 min of incubation with fluorescent opsonized E. coli (1x109/ml). 
Dotted lines indicate control staining profiles obtained after on ice incubation. Panel B: black squares 
indicate mean MFI ± SD measured, at 10-min intervals, after incubation with 1x109/ml FITC labeled 
opsonized E. coli, in granulocytes from 10 healthy controls. Empty symbols refer to mean MFI ± SD 
obtained in at least three independent experiments performed by using blood samples obtained from 
four PNH patients. All incubations were performed with whole blood samples. MFI was calculated in 
the FSC/SSC gate corresponding to the diploid PMN population. 
 
To assess the generation of ROS inside normal and GPI-defective PMN 
under different triggering conditions, we performed flow cytometry analysis 
based on ROS dependent oxidation of the DHR 123 fluorescent indicator. 
Figure 7 shows these that two independent bacterial stimuli (fMLP and E. 
coli) were unable to induce intracellular ROS production levels comparable 
to those observed in healthy controls in the GPI-defective granulocytes from 
PNH patients.  
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Figure 7. Analysis of bacterial-induced respiratory burst in PMN population. ROS production 
was measured as intracellular  fluorescence level of oxidated DHR 123. Panel A shows DHR 123 
staining levels in one representative experiment. Bold and light lines indicate staining profiles of PNH 
and control PMN after 20 min of incubation in the presence of 1x109/ml opsonized E. coli. Dotted 
lines indicate control staining profiles obtained after sample incubation on ice. Panel B shows kinetic 
profiles of oxidated DHR 123 produced by PMN from 10 to 40 min incubation in the presence of 
opsonized unlabeled E. coli and measured as MFI emission in the green fluorescence channel. Black 
squares and empty symbols indicate mean MFI ± SD obtained in the healthy control group and in 
each PNH patient, respectively. For the patient population each value represents a mean of at least 
four concordant experiments. All incubations were performed with whole blood samples. MFI was 
calculated in the FSC/SSC gate corresponding to diploid PMN population. Panel C refers data 
obtained in the four PNH patients (gray column) and in the healthy controls (white column) after 10 
min of incubation with fMLP. Histograms indicate the mean folds of increment of the green 
fluorescence levels in the PMN populations belonging to the two groups, as indicated. 
 
To investigate whether the GPI-molecule defect could account for the 
altered PMN respiratory burst in PNH, we analyzed oxidative burst 
effectiveness in the presence of receptor-independent stimuli. In this 
context, we focused on PKC-dependent pathways already demonstrated to 
be critical for ROS generation in human PMN. Then, PKC-mediated ROS 
production was evaluated by analyzing DHR123 oxidation in response to 
treatment with PMA, a pharmacological agent mimicking diacylglycerol 
(DAG) and able to recruit and extensively activate intracellular PKC. 
(Figure 8).  
 
Figure 8. Analysis of PMA-induced respiratory burst. Black Squares and empty symbols show 
kinetic profiles of oxidated DHR 123 production in normal and PNH granulocytes after incubation 
with PMA, respectively. For the patient population each value represents a mean of at least four 
concordant experiments. All incubations were performed with whole blood samples. MFI was 
calculated in the FSC/SSC gate corresponding to the diploid PMN population. 
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Notably, the percentage of reduction of ROS level in the presence of 
PMA treatment was comparable to that observed in GPI-defective PMN 
triggered by E. coli. Figure 9 shows that treatment with the BDM PKC 
inhibitor is able to differentially affect phagocytosis and respiratory burst 
induction dependent by E. coli triggering. 
 
  
 
Figure 9. Effect of PKC inhibition on E. coli uptake and respiratory burst induction of PMN. 
Panel A shows mean fluorescence levels (MFI ± SD) observed in normal PMN after 10 min of 
incubation in the presence of fluorescent opsonized E. coli alone or in the presence of 100 nM BDM, 
as indicated in the material and method section. Panel B shows oxidated DHR 123 mean fluorescence 
levels (MFI ± SD) observed in normal PMN after 10 min of incubation in the presence of opsonized 
E. coli alone or in the presence of 100 nM BDM, as indicated in the material and method section. 
Columns refer to mean (MFI ± SD) data obtained by analyzing 10 healthy donors. MFI was 
calculated in the FSC/SSC gate corresponding to the diploid PMN population. (*) indicates the 
occurrence of significant differences between the data. 
 
Thus, PKC-dependent pathways are differentially involved in the control 
of bacteria uptake and ROS production in normal PMN. 
In conclusion,  GPI-defective granulocytes from PNH patients show a 
significant increased ingestion effectiveness and a decreased oxidative burst 
induction. 
 
Study of GPI-defective compartment in PNH: GPI-defective monocytes 
from PNH patients generate impaired in vitro DC differentiation. 
To address the functional analysis of GPI-defective monocytes in PNH 
patients, we studied their ability to differentiate into DC in vitro. To 
minimize the possibility that procedures used to isolate GPI-defective 
monocytes from a mixed population could interfere with their 
differentiation, we tested only PNH patients showing more than 95% of 
GPI-defective monocytes in their peripheral blood. Figure 10 shows the 
phenotype of GM-CSF- and rIL-4 treated monocytes; as indicated, a 
significant impairment of CD1a up-regulation as well as high expression of 
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CD86 molecule was detected. These data indicate that the DC derived in 
vitro from PNH monocytes showed significant phenotype alterations.  
 
 
Figure 10. Phenotype analysis of DCs derived in vitro from PNH GPI-defective monocytes. 
Peripheral blood monocytes from one healthy donor and from three PNH patients were cultured for 7 
days  with GM-CSF and rIL-4 to obtain DC differentiation. At the end of the culture the cells were 
analyzed for the surface expression of CD40, HLA-DR, CD1a and CD86 molecules (as indicated). 
Lack of CD1a up-regulation and CD86 surface expression characterize the PNH patient DC 
phenotype. 
 
 
The impaired maturation of DC obtained from GPI-defective monocytes 
significantly affects their cytokine production and co-stimulatory activity. 
Figure 11 shows that LPS (bold line peaks in C) and CD40L treatment (bold 
line peaks in D) induced a lesser TNF-α and IL12 production in PNH DCs 
if compared with the normal DC counterpart (A and B). 
  
Figure 11. Flow cytometric analysis of TNF-α production by PNH GPI-defective DC 
Intracellular staining for TNF-α of monocyte-derived DC from one healthy control (Panels A and B) 
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and from one representative PNH patient (Panels C and D). Bold line peaks refer to TNF- α  
production after LPS (Panels A and C) and CD40L treatment (Panels B and D). Dotted line peaks 
indicate the cell incubation in medium alone (Panels A-D). A significant decrease in TNF-
 αproduction was observed in the PNH population. Data are representative of one of three 
independent experiments and were confirmed in all the PNH patients enrolled in this study. 
 
It is interesting that deficiency in CD40-dependent cytokine production 
was observed in the presence of normal surface expression of CD40 on 
PNH monocytes (Fig. 1). Thereafter, we studied the ability of DC obtained 
from the GPI-defective monocytes to co-stimulate T cell receptor (TCR)-
triggered T lymphocytes, as this function has been referred to LPS-treated 
DC already. Figure 12A shows that DC obtained in vitro from normal 
controls provided an optimal co-stimulation of TCR-triggered T cell 
proliferation at cell percentages as low as 2.5%, with a significant co-
stimulatory activity maintained even at 0.5% DC. As shown, a strong 
impairment of PNH DC in providing accessory signals for TCR-triggered T 
cell proliferation was observed.  To analyze the effectiveness of PNH DC in 
an antigen-dependent model, we also performed experiments by enrolling 
one patient and two healthy controls, referring recent bacillus Calmette-
Guerin vaccination. Therefore, to assess the ability of PNH DC to take up, 
process, and present antigens to autologous T lymphocytes in comparison 
with the normal counterpart, we analyzed their ability to elicit T cell 
proliferation against a mixture of mycobacteral antigens, as represented by 
PPD preparation. PPD-treated PNH and control DCs were thus cultured 
with autologous T cells at saturating concentration (2x104/well). As shown 
(Figure 12B), PNH-DC exhibited a significantly decreased ability to trigger 
antigen-dependent T cell proliferation compared with the control DC 
populations.  
 
Figure 12. DC differentiation in vitro of PNH monocytes generates cells with impaired ability to 
deliver accessory signals for TCR-dependent T cell proliferation. Proliferation levels of resting T 
cells triggered with anti-CD3 mAb in the presence of an increasing number of irradiated LPS-treated 
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DCs (see materials and methods) from normal donors (filled circles) and from two PNH patients 
(open squares and triangles). The proliferation was measured by [3H] thymidine incorporation after 
three days of incubation. Results are presented as mean cpm of triplicate cultures without background 
subtraction; SD was always <15%. No proliferation was observed after incubation of the T 
lymphocytes with or without anti-CD3 in the absence of irradiated DCs. Data are representative of the 
results obtained in four independent experiments. 
 
Study of GPI-defective compartment in PNH: GPI-defective T 
lymphocytes show impaired functional effectiveness. 
In order to investigate GPI-defective T lymphocytes, we analyzed their 
TCR-dependent ability to proliferate, to express activation surface 
molecules as well as to produce pro-inflammatory cytokines. The patients, 
chosen for the study, had GPI-defective T lymphocytes > 15%, as detected 
by double-labeling with anti-CD3 and anti-CD48 mAb, and showed a 
marked cytopenia. The deficiency of the GPI-linked CD48 molecule on 
defective T lymphocytes allowed a precise identification of the GPI+ and 
GPI-T cell subsets in the PNH-derived blood samples, maintaining the 
biological complexity of PNH and avoiding any functional interference as a 
result of the separation procedures. Figure 13A shows a significant 
impairment of the proliferative response of the GPI-defective (CD48–) T 
cell compartment, revealed in a representative PNH patient. By contrast, the 
percentage of proliferating CD3+CD48+ T lymphocytes was increased 
significantly in comparison with the CD48- counterpart as well as with the 
healthy control T lymphocytes. 
 
Figure 13. Analysis of TCR-dependent 
activation of the GPI+ and GPI- T cell 
compartments in PNH patients. PBMC from 
one representative healthy control and one PNH 
patient were collected and analyzed after 72 
hour of incubation with anti-CD3 mAb. Panel A 
shows the CFSE staining profiles as a measure 
of lymphocyte proliferative effectiveness (see 
Materials and Methods). GPI+ and GPI- T cells 
were gated on FITC anti-CD48 and Cychrome 
anti-CD3 mAb fluorescences (R1 and R2, 
respectively). A defective proliferation of the 
CD3+CD48- subset can be observed. Indeed, 
56% of cells undergo none or only one 
replication cycle in comparison with 24% of the 
CD3+CD48+ population and 35% of the 
CD3+CD48+ healthy control derived 
counterpart. Notably, a significant increased 
proliferation of the CD3+CD48+ lymphocytes 
from PNH patients in comparison with the 
CD3+CD48+ healthy control derived subset can 
be observed. Indeed, 70% of CD3+CD48+ cells 
from PNH patient undergo two or more 
replication cycles in comparison with 61% of 
the CD3+CD48+ healthy control derived cells 
(p<0.05).  
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Similar data were obtained by analyzing the ability of the GPI-defective T 
lymphocytes to up-regulate CD25, HLA-DR, as well as CD54 (ICAM-1: 
intercellular adhesion molecule-1) molecules in comparison with the GPI+ 
counterpart and the healthy, control-derived T cell population (Fig. 13B). 
The comparison between PNH GPI+ T cells and healthy donor lymphocytes 
revealed a significant alteration in all the parameters considered. Indeed, 
proliferation, CD25, CD54, and HLA-DR up-regulation were increased 
significantly. 
 
Figure 13B. Analysis of TCR-dependent activation of the GPI+ and GPI- T cell compartments in 
PNH patients. The graphs show the analysis of CD25, HLA-DR and CD54 surface levels, evaluated 
as mean fluorescence intensity (MFI) of the staining profiles obtained from the above populations. 
Bold lines indicate co-staining in the presence of the PE-labeled anti-CD25, HLA-DR and CD54 
mAb; dotted lines refer to the staining in the presence of the isotype control mAb. A significant 
decrease of all parameters was revealed in the CD3+CD48- population. Notably, increased expression 
of all these molecules was observed in the GPI+ T cell compartment from the PNH patient. Data are 
representative of one of three independent experiments and were confirmed in all the PNH patients 
recruited in the study. 
 
 
Figure 14 shows that a severe impairment of IFN-γ production can be 
revealed in the GPI-defective T cells A slight but consistent decrease of IL-4 
production was also observed in the GPI-defective T lymphocytes, 
confirming their impaired activation ability (not shown). By contrast, the 
comparison of the GPI+T cells from PNH patients with the healthy control 
population revealed a significant increase (P<0.05) in their IFN- γ 
production.  
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Figure 14. Flow cytometry analysis of IFN- γ  production by GPI+ and GPI- T lymphocytes from 
a PNH patient. Plots show the percentage of anti-IFN- γ mAb stained cells incubated with medium 
alone or with PMA + ionomycin. The GPI+ and GPI- CD3 lymphocyte compartment was identified by 
gating on PE anti-CD48 and Cychrome anti-CD3 mAb fluorescences (R1 and R2, respectively). As 
shown, a significant decrease in the intracellular cytokine level was observed in the GPI-defective 
population. Data are representative of one of three independent experiments and were confirmed in all 
the PNH patients recruited in the study. 
 
Taken in all, this results suggest that growth vantage of GPI-defective 
compartments is likely dependent on an increase of functional effectiveness 
of GPI-defective cells. Indeed, analysis of GPI- PMN, DC and T cells 
revealed an impairment in their biological and physiological functions. 
These data support the occurrence of an extrinsic selective pressure, 
favoring the expansion of GPI-defective clone, whose autoimmune origin 
need to be investigated.  
 
Study of immunological tolerance regulation in PNH: TCR-triggered 
CD4+CD48+ lymphocytes from PNH patients show functional 
persistence of surface CD154 expression  
Given the relevance of CD40 pathways in maintenance of immune 
tolerance78, we investigate more deeply such pathway in PNH patients. 
Thus, the kinetics of CD154 induction occurring in GPI+ and GPI-T 
lymphocytes from PNH patients has been analyzed. As shown in Figure 15, 
after 8 h of incubation with anti-CD3 CLB-CD3/E mAb, a significant up-
regulation of the CD154 molecule was observed in healthy control CD4+ 
lymphocytes, as well as in the GPI+ and GPI–defective compartments of 
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PNH patients. CD48+CD4+ cells, which represent the GPI+ population in 
PNH, showed a significant increase in their surface CD154 expression when 
compared with the GPI-defective CD4+ counterpart and the CD4+ cells from 
the healthy controls. 
 
 
  
Figure 15. Analysis of TCR-dependent CD154 expression on the GPI+ and GPI- CD4+ 
population from two PNH patients, compared with healthy donors. The plots refer to the staining 
of CD48+CD4+ and CD48-CD4+ (R1 and R2, respectively) with anti-CD154 mAb after 8 hour of 
incubation in the presence of anti-CD3 mAb. A significant impairment in CD154 induction was 
observed in the GPI-defective population, as compared with the GPI+ counterpart. Notably, an 
increased surface level of this molecule was observed in the GPI+ CD4 population from the PNH 
patients in comparison with the healthy controls. Data are representative of one of four concordant 
experiments. 
 
 
To assess the functional relevance of the increased CD154 up-regulation on 
the surface of anti-CD3-treated T cells from PNH patients, we evaluated the 
ability of these populations to up-regulate the CD23 molecule on the surface 
of B lymphocytes from healthy controls. Indeed, the up-regulation of this 
molecule has been described as a relevant target for CD40 triggering79. 
Therefore, we co-cultured normal PBMC in the presence of irradiated 
healthy donor or PNH-derived PBMC, previously incubated with anti-CD3 
mAb for 8 or 48 h. After overnight culture, the level of CD23 was measured 
on B lymphocytes, as identified by CD19 co-staining. As shown (Fig. 16), a 
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significantly increased up-regulation of this molecule was observed in the 
presence of PNH as compared with control PBMC collected after 8 h from 
CD3 triggering (P<0.05). 
 
Figure 16. CD3 triggered PBMC from PNH patients are able to up-regulate CD23 surface levels 
on control B cells. The graph refers to the level of CD23 antigen expression on control B 
lymphocytes, identified by co-staining with anti-CD19 mAb, after overnight incubation in the 
presence of 30 Gy irradiated PNH (gray columns) or healthy control (white columns) PBMC, pre-
treated with anti-CD3 mAb or medium, as indicated. PNH cells significantly up-regulated the CD23 
molecule on control B cells both after 8 (Panel A) and 48 hours (Panel B) of CD3 triggering. Notably, 
healthy control derived PBMC showed significant ability to up-regulate B lymphocyte CD23 only 
after 8 hours of anti-CD3 incubation. Data refer to means of fluorescence levels (MFI) obtained in 
three independent experiments. Standard deviations are depicted on the top of each bar. The symbol * 
indicates the statistical significant differences (p<0.05), in comparison with normal control group.  
 
 
Notably, also, the medium-cultured PNH cells, but not the healthy control, 
showed significant ability to up-regulate the CD23 molecule on B 
lymphocytes. Moreover, lymphocytes from PNH patients, collected after 48 
h of anti-CD3 incubation (Figure 16B), revealed a persistent ability to up-
regulate CD23. The healthy control cells, collected after the same culture 
period, were substantially unable to modify CD23 expression on the surface 
of the target population (P<0.05). The observed effects were partially (from 
30% to 50%) inhibited by anti-CD40 mAb treatment of the target 
population, demonstrating the involvement of CD40-dependent pathways 
(data not shown). To assess whether the increased CD23 up-regulation on B 
cells could correlate with the expression of CD154 on the lymphocytes of 
PNH patients, we analyzed CD154 kinetic expression on the 
CD4+population after incubation with the anti-CD3 mAb for 8, 24, and 48 h. 
As shown in Figure 17, a significant persistence of the CD154 molecule on 
the CD48+CD4+ cells from PNH patients was observed after 24 and 48 h 
from anti-CD3 treatment. In addition, a slight but consistent expression of 
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CD154 was observed after 48 h treatment with medium in the 
CD48+CD4+cells from the PNH patients.  
 
 
Figure 17. Kinetics of TCR-dependent CD154 induction on CD4+CD48+ lymphocytes of one 
representative healthy control and two PNH patients. Staining profile of anti-CD154 mAb on 
CD4+CD48+ lymphocytes. Plain and dotted lines indicate anti-CD3 and medium incubation, 
respectively. The CD154 up-regulation after 8 hours is accompanied by a consistent persistence of 
CD154 surface expression after 24 and 48 hours of anti-CD3 incubation in the PNH patients, but not 
in the representative healthy control. Data refer one of three concordant experiments and were 
confirmed in all the PNH patients recruited for the study. 
 
A specific set of HLA alleles is significantly associated with the 
occurrence of PNH. 
Since the relevance of HLA genes as a susceptibility factor in 
autoimmune diseases, we analyzed HLA class I and Class II alleles in our 
cohort of PNH patients.  To this aim, molecular typing of HLA Class I and 
Class II genes in a homogeneous large group of Italian PNH patients 
compared with unrelated healthy controls with the same genetic background 
has been performed. Significant differences in the frequency of several 
Class I and Class II HLA alleles between PNH patients and controls are 
shown in Table I. 
The frequency of HLA-A*0201 allele (52.5% vs. 32.2%; pc<0.05) is 
increased in our series of PNH patients. Moreover, we found an increased 
frequency of B*1402 (23.8% vs. 5.3%; pc<0.001) and Cw*0802 alleles 
(23.8% vs. 5.9%; pc<0.005).  
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The allele DRB1*1501, already associated with various autoimmune 
disorders and with PNH in the American and Japanese patients, was 
significantly increased in our series of Italian PNH patients (21.1% versus 
5.3%; pc<0.01). In addition, the frequency of DRB1*01 (31.6% versus 
10.9%; pc<0.05), is increased, but no specific association with the 
DRB1*0101 or DRB1*0102 allele has been found. Our study revealed that 
the haplotype B*1402, Cw*0802 (23.8 % versus 5.3%; p<0.0005) as part of 
the extended haplotype A*33, B*1402, Cw*0802, DRB1*0102 (10.5% 
versus 0.66%; p<0.005) were, respectively, 4 and 15 times more frequent in 
PNH patients than in controls.  
Thus HLA alleles are associated with the occurrence of PNH in our 
cohort of PNH patients. It is intriguing that these associated alleles are 
arranged in an extended haplotype (A*33, B*1402, Cw*0802, DRB1*0102) 
whose Mediterranean origin has been described.  
 
Immunological asset in MDS patients: Activated cytotoxic T cells 
recruitment in MDS bone marrow  
The analysis of PNH patients revealed significant alterations of immune 
effectors compatible with an immune-mediated selective pressure able to 
account for the expansion of GPI-defective hematopoiesis. To evaluate the 
immunological asset in MDS patients, an immunophenotipic analysis of BM 
and peripheral blood samples has been performed, focusing on effector 
lymphocyte populations. As control, a group of healthy individuals has been 
analyzed. The study showed a significant recruitment (p=0,0255) of 
CD3+CD8+ CTL in MDS BM as compared with peripheral blood. No 
significant difference in CD3+CD4+ T cells has been observed between BM 
and blood (Figure 18). In addition, no significant difference has been 
revealed by comparing both CD3+CD4+ and CD3+CD8+ T cells percentage 
between MDS patients and controls (data not shown). 
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Figure 18. BM recruitment of effector citotoxic T cells.  Multiparametric analysis of MDS BM and 
peripheral blood, performed by immunofluorescence and flow citometry, shows a significant increase 
of CD3+CD8+ T cell percentage in BM of MDS patients, compared to peripheral blood. (p=0,0255). 
No significant differences have been observed for CD3+CD4+ T cells between the two compartments. 
The analysis has been performed on lymphoid population. 
 
In order to more deeply investigate the role of CD3+CD8+ CTL in MDS 
pathogenesis, these lymphocyte subsets have been analyzed in different 
prognostic groups: as shown in figure 19 the percentage of BM CD3+CD8+ 
T cells was increased in comparison to peripheral blood in IPSS Low 
(p=0,042) e IPSS INT1 (p: 0,0027) groups. No significant difference has 
been observed in INT2 group.  
Figure 19. BM recruitment of effector citotoxic T cells in MDS disease stages. Statistical analysis 
of BM and peripheral blood effector T cells in different score groups. Difference between CD3+CD8+ 
citotoxic T cell percentage in BM and blood is significant in Low (p=0,042) and Int1 groups 
(p=0,0027). No significant difference is observed is INT2 group.  
 
 
These data suggested a BM recruitment of effector CTL in MDS patients in 
first disease stages. To quantify the phenomena, the CD4+/CD8+ T cell ratio 
in BM and peripheral blood of MDS patients at different disease stages has 
been evaluated. The statistical analysis revealed a significant difference of 
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CD4+/CD8+ T cell ratio between MDS BM and peripheral blood in IPSS 
Low (p=0,0251) e INT1 (p=0 ,0042) groups. (Figure 20) 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Comparative analysis of CD4/CD8 T cell ratio in BM versus peripheral blood in 
MDS patients. CD4/CD8 T cell ratio in BM and in peripheral blood of MDS patients, belonging to 
Low, Int-1 and Int-2 prognostic groups, are indicated. Statistical analysis of data revealed the 
occurrence of a significant decrease in BM CD4/CD8 T cell ratio in Low (p=0.02) and in Int-1 
(p=0.004) prognostic groups, as compared with the peripheral blood. No difference in the BM versus 
peripheral blood distribution has been observed in the Int-2 MDS risk group. 
 
 
To evaluate the role of these effector CTL in MDS progression, the 
expression levels of CD54 (intracellular-adhesion cell-1) on MDS CD8+ and 
CD4+ T cells has been evaluated. During activation, T cells up-regulate a 
great number of surface molecules, able to improve the functional 
effectiveness.  The cytofluorimetric analysis of MDS bone marrow samples 
showed a significant decrease of CD54 expression on CD8+ (p=0,01)  and 
CD4+ T cells (p=0,03) in High/Int2 score groups, compared to Low/Int1 
MDS groups and healthy control (Figure 21). This data could suggest an 
involvement of activated effector T cell population in MDS progression to 
neoplastic disease (AML). 
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Figure 21: Analysis of activation state of effector T cells. CD3+CD4+ and CD3+CD8+ BM T cells 
show decreased CD54 expression in INT2 disease score groups in comparison to Low group. CD54 
(ICAM-1) is an adhesion molecule, generally up-regulated after activation. Statistical analysis reveale 
a significant difference between two groups for two lymphocite populations, CD8+ (p=0,01) and 
CD4+ T cells (p=0,03) 
 
Immune regulation in MDS: Regulatory T cells in different disease 
stage 
Since the relevance of Treg cells CD4+CD25+FoxP3+ in regulation of 
effector T cells functional effectiveness, as well as in tumor immune-
surveillance control, the levels of this cell population in BM and peripheral 
blood of MDS patients has been also investigated. Preliminary data, 
obtained using immunofluorescence and flow cytometric analysis, revealed 
a significant increase of Treg cell percentage in the BM of High/Int2 disease 
score group, in comparison with Low/Int1 groups and healthy donor (Fig. 
22). No significant difference has been observed between Treg cell levels in 
peripheral blood of different disease score MDS groups (not shown). 
 
 
 
  
 
 
 
 
 
 
 
Figure 22: Analysis of Treg in BM of MDS patients. Treg percentage in BM of MDS patients 
belonging to Low, Int-1 and Int-2 groups, are indicated in comparison with healthy controls. As 
shown, statistical analysis of data revealed the significant increased levels of BM regulatory T cells in 
the Int-2 MDS group as compared with the Low risk and the controls (p=0.03 and 0.01, respectively). 
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Discussion 
 
This study indicates that immune-mediated mechanisms can underlie the 
occurrence of hemopoietic disorders characterized by clonal expansion of 
defective and/or dysplastic clones in PNH and MDS patients. Indeed, 
functional defects characterize both the innate and adaptive GPI-defective 
immune compartments in PNH patients. In addition, significant increased 
frequency of HLA-DRB1*1501 allele (p<0.01) and of the B*1402, 
Cw*0802 haplotype (p<0.0005) as part of the extended Mediterranean 
haplotype A*33, B*1402, Cw*0802, DRB1*0102 (p<0.005) has been 
revealed in our cohort of PNH patients. Moreover, an altered CD40-
dependent pathway and regulatory T cell tolerance control has been 
observed in PNH and MDS patients, respectively 
 
Innate and adaptive GPI-defective compartments in PNH patients: the 
granulocytes. 
This study suggests that GPI-defective granulocytes exhibit enhanced 
ingestion capability associated with impaired production of ROS in response 
to bacterial stimulation in PNH patients. This functional behavior seems to 
be specifically associated with PNH. Indeed, nor patients affected by 
Chronic Granulomatosis Disease (CGD), caused by a defect in the NADPH 
oxidase genes, with their heterozygous carriers, neither neutropenic 
individuals showed similar alterations. 
The contact between opsonized bacteria and granulocytes is mainly 
mediated by specific receptors for Fc fragment of immunoglobulins and for 
complement fractions. The recruitment of both receptors has been described 
to generate synergistic effects80, as compared with single receptor 
engagement. In addition, increased serum concentration of complement 
fractions has been associated with over-expression of the specific membrane 
receptors and enhancement of their affinity81,82. Indeed, increased binding of 
the third component of Complement (C3) on PNH granulocytes has been 
observed83 suggesting the prevalent occurrence of a complement-mediated 
ingestion pathway in GPI-defective PMN. 
. 
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The ex vivo altered phagocytosis, observed in GPI- PMN from PNH 
patients, suggests the presence of a cell population altered in vivo. The 
absence of the GPI-linked CD55 and CD59 molecules, that mediate 
complement inactivation, increases the level of activated complement 
fractions in PNH. The availability of such activated complement 
components on the surface of GPI-defective PMN could act as a chronic 
triggering factor, as described for PNH platelets84. The increasing of 
activated C3 molecules, followed by over expression of higher affinity 
receptors on PNH granulocytes81, may thus represent a chronic triggering 
element for the phagocytic process, likely able to mediate an enhanced 
ingestion ability by GPI- PMN.  
The involvement of multiple pathways in regulating the engulfment 
processes points to the dispensable role for PKC in early phagocytosis 
processes, also suggesting the ability of integrin complement receptors to 
act as PKC depleting stimuli85 in PNH patients. Our data confirm such 
observations suggesting the dominant role of PKC for respiratory burst 
induction with less relevant involvement in bacterial ingestion pathways. 
Moreover, our data indicate the occurrence of both increased ingestion 
ability and severe ROS production impairment in GPI-defective PMN. The 
analysis was performed by using two distinct bacterial stimuli, as 
represented by N-formil peptides and opsonized E. Coli recognized by 
specific receptors on PMN cell membrane. Defective ROS production was 
also observed after respiratory burst triggering by PMA, a DAG–
homologous widely used as extensive PKC activator86. This biological 
behavior seems to characterize GPI-defective PMN in PNH, if compared 
with neutropenic or CG patients. On the basis of this observation, one could 
rule-out that increased engulfment could represent only a compensatory 
mechanism for the deficient burst induction.  
 The observation that two independent bacterial stimuli and PMA 
triggering were unable to induce normal ROS production in GPI-defective 
PMN might indicate the occurrence of decreased levels of intracellular 
PKC. In this regard, a possible relationship between enhanced C3 molecule-
dependent phagocytosis, chronic intracellular PKC depletion and impaired 
efficiency of the respiratory burst in the GPI-defective granulocytes can be 
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hypothesized in PNH patients. Notably, the occurrence of activation-
induced depletion of PKC, as a pathogenetic mechanism for impaired ROS 
production, has been recently demonstrated in septic patients87.  
Thus, the involvement of multiple intracellular pathways in the 
regulation of ingestion mechanisms88 and the key role of PKS in mediating 
oxidative burst induction can account for the persistence of an increased 
ingestion ability in the presence of an impaired respiratory burst induction in 
human PNH granulocytes. 
These alterations, together with the recently described defective adhesion 
and migration of PNH granulocytes, dependent on the absence of the GPI-
linked molecules CD15789 and GPI-8090points to the possibility that a 
decreased functional effectiveness of the GPI-defective PMN compartment 
could impair the  innate immune response against pathogens, mainly 
compromised by cytopenia, in PNH patients. The clinical relevance of such 
functional defects needs more conclusive assessment. 
 
Innate and adaptive GPI-defective compartments in PNH patients: the 
monocytes and dendritic cells. 
Monocytes and granulocytes, the main effector populations of the 
innate compartment, play a key role in orchestrating the immune response. 
Indeed, they mediate essential effector activities (phagocytosis and the 
oxidative burst) to control pathogen survival and expansion91 but are also 
involved in the activation of the adaptive immune response92.  
Recognition of the pathogens as well as the indirect sensing of 
infections trough inflammatory cytokines are involved in entering 
monocytes into an integrated developmental program called DC 
differentiation93. Monocyte-derived DC represents a key cell population for 
antigen-dependent activation of naive T lymphocytes94 . Others and our data 
showed that a majority of granulocytes and monocytes in peripheral blood 
of PNH patients are GPI-defective. 
Our data show that the treatment with GM-CSF and rIL-4 of GPI-
defective monocytes was unable to generate in vitro functional DCs. GM-
CSF and IL-4 receptors are expected to be functional in PNH patients, since 
both molecules do not need a GPI anchor to be expressed on the cell 
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membrane. Indeed, GM-CSF receptor-dependent medullar mobilization of 
GPI defective precursors was described in PNH patients.95  
DCs are key regulators of the immune response and their 
differentiation reflects an ordered series of events involving specific gene 
expression patterns, intracellular protein targeting and organelle biogenesis 
leading to potent immuno-modulatory functions.94,96. The up-regulation of 
GPI-linked molecules, as represented by the CD48 antigen, has been already 
described as part of the DC differentiation program.97 Therefore, it is 
possible that cell-to-cell functional interactions involving GPI-linked 
structures affect monocyte differentiation into DC. In addition, an 
involvement of GPI-linked structures in the molecular machinery 
underlying in vitro monocyte-DC differentiation could be hypothesized.  
The lack of CD1a surface expression, the presence of CD86 and the 
mannose receptor expression are the hallmark of the DC population 
obtained in vitro from the PNH monocytes. CD1a represents a third class of 
MHC molecules able to associate with a wide range of lipids and 
glycolipidic antigens to be presented to CD8+, CD8-CD4- and γδ-T-
lymphocytes.98 In addition, the critical involvement of CD1 antigens in the 
DC-dependent activation of regulatory T and NKT lymphocytes in both 
mice and human models has been suggested.99 Several observations indicate 
CD1 down-modulation, combined with a variable CD86 surface expression 
as a common feature of DC functional impairment occurring in cancer 100 as 
well as in immune-deficiency models101.  
Our data show a severe impairment of the DCs obtained from GPI-
defective monocytes to deliver optimal accessory signals to TCR-triggered 
T lymphocytes, even in the presence of high levels of CD86 co-stimulatory 
molecule. In this respect, the observed lesser cytokine production and the 
availability of putative inhibitory molecules by DCs could account for such 
impairment in PNH. The level of co-stimulation depends on the expression 
of co-stimulatory molecules as well as on the stability of the immunological 
synapse102. In this context, the relevance of a correct recruitment of the lipid 
rafts, membrane domains rich in signaling molecules as well as in GPI-
linked structures,103 for the achievement of an optimal primary T-cell 
response  has been established.104 
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The observation that GPI-defective monocytes generate impaired DC 
differentiation in vitro suggests the existence of a defect in the physiological 
cross talk between the innate and the adaptive immunity in PNH patients, 
whose monocyte compartment is completely GPI-defective. In addition to 
the frequent neutropenia and to the observed functional impairments of 
PNH neutrophils, the altered DC-differentiation of PNH monocytes may 
have also a role for the increased susceptibility to infections often observed 
in PNH patients.105 
 
Innate and adaptive GPI-defective compartments in PNH patients: the 
T lymphocytes 
This study reveals the occurrence of significant functional alterations 
in GPI-defective T cell compartment. Severe defects in TCR-dependent 
proliferation, CD25, CD54 and HLA-DR surface expression and cytokine 
production in the GPI-defective T cell population were demonstrated. 
 In this regard, the inability of healthy donor monocytes to overcome such 
impairment strongly supports the occurrence of some defects in the TCR-
dependent activation machinery of the GPI-defective T lymphocytes. These 
data confirm and extend previous reports showing severe dysregulation of 
the immune system in a Pig-a-/Rag-/- chimeric murine model106, impaired 
lectin-triggered proliferation107 and TCR-dependent signaling in GPI- T 
cells108. 
In addition, a relationship between the lack of GPI-linked proteins 
and the occurrence of functional impairment of immune effectors, seem to 
be confirmed also in lymphoid compartment. 
 Several evidences suggest that lipid rafts regulate dynamic interactions 
between T cell signaling proteins109. Thus, raft micro-domains could 
represent key platforms that couple events outside the cell with signaling 
pathways inside the cell, also trough GPI-linked protein-dependent 
interactions.110 Therefore, the involvement of the lack of GPI-linked 
proteins, observed in PNH, in the pathogenesis of the impaired TCR-
triggered activation could be hypothesized. 
Our observations, as a whole, strongly support the possibility that GPI-
defective clones have to evolve under permissive conditions, in a 
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background that impairs normal haematopoieis. Indeed, all the GPI-
defective immune-effectors by us analyzed showed significant functional 
impairment in PNH patients. Moreover, a number of data indicate that not 
mutated PIG-A+ stem cells are markedly impaired in their growth in PNH 
patients111.  
 The possibility that immune-mediated mechanisms might account for the 
clonal dominance of the PIG-A mutation and for the development of PNH 
has been already suggested36,39,105,112. In this regard, PNH patients showing 
a marked cytopenia, likely suggesting the occurrence of an active bone 
marrow failure process, are expected to represent optimal models to address 
such hypothesis. In order to address such issue, we analyzed GPI+ T cell 
compartment in such a group of PNH patients. Our data indicate the 
occurrence of significant increase of TCR-dependent proliferation as well as 
of CD25, CD54 and HLA-DR surface expression. In these patients a 
possible defective regulation of T cell homeostasis, also affecting the 
functional asset of T lymphocytes, could be consequent to a perturbation of 
immune tolerance. Such condition could promote the generation of hyper-
activated T cell effectors accounting for the increased response to TCR-
triggering by us observed in vitro. In our experimental model the 
employment of multi-parametric immune fluorescence technique allows the 
analysis of GPI+ compartment maintaining the biological complexity of 
PNH and avoiding any functional interference due to the separation 
procedures. Therefore, the increased activation level reached ex vivo by the 
GPI+ T cell compartment of PNH patients might suggest the presence of a T 
cell population, which is altered even in vivo. In this context, the presence 
of a chronic stimulation, likely consequent to a defective control of 
activated complement components, as suggested for PNH platelets84 cannot 
be ruled out.  
 
Analysis of tolerance control mechanisms in PNH: the CD40-CD40 
ligand pathway 
Interactions between co-stimulatory ligands and their receptors are 
critical for activation of T lymphocytes, prevention of tolerance and 
development of T cell-dependent immunity. Moreover, only a few co-
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stimulatory molecules are expressed on T cells in a constitutive fashion, 
whereas a majority is induced following cell activation subsequent to 
antigen recognition by TCR113. The CD40-dependent pathways have been 
described as relevant for the control of both innate and adaptive immune 
responses and for the achievement and maintenance of immune tolerance114. 
Given the relevance of these pathways, a tightly regulated expression of 
CD154, the CD40 ligand, could be necessary to maintain the antigen 
specificity of T cell activation. 
 This study shows a significant increase and the functional persistence of 
CD154 on TCR-triggered CD4+GPI+ lymphocytes from PNH patients. Our 
data indicate that 8 hour anti-CD3 treated lymphocytes from PNH patients 
showed increased ability to up-regulate surface CD23 levels on B cells, 
already demonstrated to represent a relevant target for CD154-dependent 
triggering of B lymphocytes78. Moreover, we observed that 48 hour anti-
CD3 cultured lymphocytes from PNH patients, but not from healthy 
controls are able to up-regulate such molecule. These effects were 
significantly, but not completely inhibited by anti-CD40 mAb target 
treatment. The observed CD154 persistence on 48 hour anti-CD3 treated 
CD4+CD48+T cells from PNH patients are expected to likely account for 
such effect. 
 Altered persistent expression of CD154, the CD40 ligand, has been 
described in pathological conditions characterized by a defective control of 
autoreactive clones115, as represented by SLE. Therefore, the persistence of 
a functional CD154 molecule on the TCR-triggered CD48+CD4+ 
lymphocytes could be suggested as relevant for the possible immune-
mediated pathogenesis of the disease in PNH.  
The observation that 8 hour medium-treated CD48+CD4+ 
lymphocytes from PNH patients show significant ability to up-regulate 
CD23 surface levels, in the absence of detectable CD154 expression, points 
to the involvement of both CD40-dependent and independent pathways in 
mediating such effects. These data, according with the presence of a skewed 
T cell repertoire in PNH116 and AA patients39 suggest the occurrence of 
dysregulation of the biological mechanisms underlying tolerance 
maintenance in PNH patients.  
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Looking for immune-mediated mechanisms in GPI-defective clone 
expansion in PNH: the HLA genes 
The association between an auto-immune disease and certain HLA alleles 
has been attributed to the ability of these alleles to bind and present specific 
peptide auto-antigens to T cells with the appropriate receptors. 23,117 Our 
data suggest the involvement of a large shared peptide ligand, able to bind 
DRB1*1501 specificity, in all the populations of PNH patients till now 
analyzed118,119.  In addition, the significant increase of the haplotype 
B*1402, Cw*0802, as part of the extended Mediterranean haplotype A*33, 
B*1402, Cw*0802, DRB1*0102 (p<0.0005 and p<0.005, respectively) 
suggest the specific involvement of other HLA-dependent factors in our 
Italian PNH population.  
The described association between certain HLA types and a higher 
risk to develop PNH may provide further insight into the mechanism for 
selective damage to normal (GPI+) hematopoiesis, which is responsible for 
the clonal expansion of GPI-defective hematopoiesis that ultimately gives 
rise to clinical PNH. Indeed, the possibility that critical target molecules 
could be identified in order to propose new innovative therapeutical 
approaches has to be considered. 
Moreover, our findings might appear to be in conflict with recent 
work, showing that patients with different HLA types have expanded T-cell 
clones with the same or very similar TCR-β sequences116, suggesting that 
the target auto-antigen may not be a peptide. However, other not mutually 
exclusive interpretations are possible:  
- Since HLA genomic region contains many non-HLA genes with 
putative or proven immune functions, 117 the association here reported 
could be related to an increased ability to produce pro-inflammatory 
cytokines that may damage hematopoiesis. The fact that we have found 
a much stronger association with an extended haplotype than with any     
individual HLA allele is in keeping with this hypothesis.  
- Peptides bound to certain HLA alleles may recruit T cells that, directly 
or indirectly, will in turn enhance the response to a non-peptide antigen.  
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- the target auto-antigen could be a peptide in some patients with PNH 
and a non-peptide in others. 
 
Tolerance control dysregulation and expansion of dysplastic clones in 
MDS: BM regulatory T cells. 
Taken in all, our data support the hypothesis that an immune-mediated 
attack against a normal Stem precursor could underlie the emergence and 
expansion of GPI-defective clone/s in PNH. Moreover, the analysis of MDS 
patients revealed the occurrence of significant alterations in the BM 
recruitment/activation state of immune effectors. Indeed, our analysis 
showed a significant BM recruitment of CD8+ CD3+ lymphocytes in the BM 
samples of MDS patients. The presence of such cytotoxic effectors was 
specifically observed in the BM of MDS patients belonging to the low/INT1 
risk group, while no significant differences with the controls was observed 
in the high score disease group. Moreover, the analysis of the expression 
levels of CD54 (ICAM-1), whose expression has been related to the 
activation state of CD4+ and CD8+ effector T cells, showed similar 
distribution. This results support the hypothesis that BM immune effectors 
could have a role in the pathogenesis of MDS. 
One of the model of MDS development proposes the occurrence of a 
multi-step process during which the neoplastic transformation of 
hematopietic stem cell could induce the expression of neoantigens, able to 
generate an immune-mediate attack. Moreover, the possibility that an 
autoimmune attack against normal stem precursor could occur needs to be 
investigated. Cytofluorimetric and molecular (spectratyping) data, showed 
the presence of oligoclonal T cell repertoire in MDS BM120,121,122, while both 
RT-PCR and immunoistochemistry analysis revealed the increase of 
proinflammatory cytokines in MDS BM123. The possibility that such a 
proinflammatory microenvironment could represent the main cause of 
increased apoptosis of BM precursors, has been also suggested124,125. Indeed, 
Stifter et al. showed a close relationship between TNFα serum levels and 
anemia in AR and AREB MDS subtypes, indicating a relevant role of the 
cytokine with increased apoptosis of erythroid precursors in earlier state of 
disease126. Recently, microarray data, revealing the selective induction of 
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IFN-gamma-dependent genes in BM CD34+ precursors in PNH and MDS, 
confirmed the critical relevance of a pro-inflammatory microenvironment in 
the pathogenesis of both diseases127.  
Our data, according with recent reports showing that 
immunosuppressive therapy with anti-thymocyte globulin and/or 
cyclosporine A can lead to lasting hematological responses and abrogation 
of pathogenetic T-cell clones in low-risk MDS128,129, revealed an increase of 
CD3+CD8+ lymphocytes as well as of their CD54 surface levels in BM of 
Low/INT1 MDS patients. Thus the occurrence of CTL-dependent immune-
mediated mechanisms in the earlier disease stages of MDS might be 
hypothesized.  
Treg cells play an important role in the control of auto-reactive 
effectors as well as in the regulation of immune recognition of transformed 
clones. Moreover, recent data have been demonstrating that BM might 
harbor CD4+CD25+ Tregs and that can function as a reservoir for them130, 
thus representing an important organ to fine tune T-cell immunity by 
modulating Treg trafficking.  
Recent reports indicate the occurrence of defective Treg response in 
AA131and an increase of such regulatory population in the peripheral blood 
of MDS patients belonging to more advanced disease stage132. Our 
preliminary data revealed a significant increase of CD4+CD25+Foxp3+ BM 
Treg cells in INT2/High score MDS groups, compared with the Low/INT1 
patients. Therefore, the possibility that the occurrence of Tregs defects in 
BM may be associated, in low-risk MDS, with the emergence of auto-
reactive T-cell clones, responsible for BM hypoplasia can be suggested. In 
addition, an expansion of this regulatory population in the late disease 
stages, could represent an effective escape mechanism of the dysplastic 
clone/s to immune-mediated control of transformation, as described in other 
malignant diseases.  
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Growth vantage and/or immune-mediated escape in hematopoietic 
disorder: the role of MHC molecules 
 
A CASE REPORT 
Since the great number of evidences that suggest the relevance of 
immune effectors in emergence of dysplastic clones, we investigated the 
pathogenesis of monocytosis and severe neutropenia in a MDS patient 
showing BM Natural Killer (NK)  expansion.  
A 73 year old MDS patient presenting mild anemia and neutropenia, 
showed CD56+CD3- NK cell expansion in BM and peripheral blood with 
CD14+CD56+ monocytosis and neutropenia. In this context, to assess the 
possibility of clonal origin of expanded NK cell population, phenotypic 
analysis of these cells has been performed. The CD56+CD3- NK cells 
present a random distribution of specific NK receptor both in BM and 
peripheral blood, suggesting polyclonality of these expanded cells. In order 
to investigate the functional effectiveness of NK cells, a cytotoxicity assay 
has been performed, using K562 cell lines as a target, as previously 
described133. The study revealed no significant differences between NK 
cells isolated from the MDS patient and from healthy donor. In this context, 
in order to address the possible role of NK cells in defective granulocyte 
maturation and expansion of CD14+CD56+ monocytes, a cytotoxicity assay 
has been performed against granulocytes and monocytes isolated from MDS 
patient and healthy control. A strong increase of NK-cell mediates lysis 
susceptibility has been observed for MDS granulocytes; no lysis has been 
observed against MDS monocytes and against healthy donor derived 
monocytes and granulocytes. This result suggested a possible role of these 
effector cells in neutropenia. To better understand the different NK-lysis 
susceptibility of MDS monocytes and granulocytes, MHC and MHC-
associated molecules asset, able to regulate the cytotoxic function of these 
cells, has been investigated. Cytofluorimetric analysis showed a sever defect 
of non classic-MHC molecule HLAE on the surface of MDS patient 
monocytes and granulocytes, compared with healthy donor cells. It has been 
described that alteration of NK cell-target interactions, can be considered as 
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pathogenetic cofactor operating in vivo together with other immunological 
mechanisms, all contributing in giving the final pathological treat. In Celiac 
Disease, recent data, published by our group134, revealed that gliadin could 
have a detrimental role in the regulation of NK cell-immature DC (iDC) 
cross-talk with consequences on the adaptive immunity activation. iDC 
gliadin treatment inhibits NK cell cytoxicity against iDC via the interaction 
between CD94/ NKG2A and HLA-E. Indeed, gliadin increases the HLA-E 
expression on iDC and the blocking of CD94/NKG2A receptor on NK cells 
restores their killing against gliadin-treated iDC. Moreover, the relevance of 
this molecule for the pathogenesis of hematopoietic diseases135 has been 
suggested. Since the severe deficit of HLAE on the two different myeloid 
populations, the attention has been focused on the other MHC molecules; 
the analysis revealed the presence of decreased levels of HLA-class I 
expression on MDS granulocytes surface, compared to  MDS monocytes 
and to healthy donor cells. These data could support the hypothesis that a 
different expression of classical MHC molecules could account for the 
different susceptibility of granulocytes and monocytes to NK lysis. In 
addition, phenotypic analysis of myeloid compartment showed abnormal 
expression of CD178 (Fas-Ligand) on CD14+CD56+ monocytes. To assess 
the functional relevance of the increased CD178 up-regulation on the 
surface of monocytes from this MDS patient, the ability of these cells to 
induce apoptosis in a CD95 positive (CD178 receptor) Jurkat T cells has 
been performed. After co-culture of Jurkat cell line and monocytes isolated 
from MDS patient and healthy control, the apoptosis levels, measured as 
Annexin V-positive cells, has been analyzed. , The percentage of positive 
cells in presence of MDS monocytes was significantly increased  in 
comparison with healthy donor. This result could suggest that monocytes 
could contribute to defective granulopoiesis in this MDS patient. 
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Conclusions 
 
This study analyzed two hematological disorders, showing different 
clinical manifestations, in which defective or dysplastic clonal 
hematopoiesis develops through several lineages and replaces the normal 
counterpart: PNH and MDS. In particular, the critical involvement of 
immune-mediated mechanisms for the pathogenesis of clonal dominance of 
the GPI-defective compartment and for selection/shaping of dysplastic clone 
has been investigated.  
To this aim, the immunological asset of PNH patients has been 
analyzed, focusing on the functional difference between GPI+ and GPI- 
defective compartments. The study revealed a critical functional impairment 
of GPI-defective cells, both in innate and adaptive compartments, indicating 
that the growth vantage of GPI-defective clone is relative. In addition, a 
significant increase in the functional effectiveness of PNH patients GPI+ T 
cells has been revealed. Therefore, the increased activation level reached ex 
vivo by the GPI+T cell compartment of PNH patients might suggest the 
presence of a T cell population, which is altered even in vivo. This data 
strongly support the possibility that GPI-defective clones could evolve 
under permissive conditions in a background that impairs normal 
hematopoieis. Since the relevance of CD40-dependent pathways for the 
control of both innate and adaptive immune responses and for the 
achievement and maintenance of immune tolerance, the study of CD40-
dependent pathways in PNH patients has been addressed. The study 
revealed a functional persistence of CD154 (CD40-ligand) on GPI+T cells, 
as previously described for other autoimmune disease. This evidence 
suggests that the alterations of CD40-dependent tolerance control could 
underlie an immune-mediated bone marrow failure likely associated with 
the expansion of the PIG-A defective clone. HLA represent a major 
susceptibility factor for autoimmune diseases. In this context, analysis of 
HLA alleles in PNH patients revealed an increased frequency of a specific 
set of HLA alleles in a large cohort of PNH patients. This result may 
provide further insight into the mechanism for selective damage to normal 
(GPI+) hematopoiesis, which is responsible for the clonal expansion of GPI-
defective hematopoiesis that ultimately gives rise to clinical PNH. 
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In order to investigate whether the growth advantage of the 
dysplastic, often clonal hematopoiesis, in MDS patients, could be dependent 
on damaging mechanisms preferentially affecting the normal counterpart in 
the bone marrow microenvironment, the study addressed the BM 
immunological asset in a group of MDS patients, at different disease stage. 
The analysis revealed a BM recruitment of CD3+CD8+ effector T cells in 
MDS patients in earlier stage of disease; in the same patients, these cells 
showed an increase of CD54 expression, whose critical relevance for CTL 
effector function has been largely described. These results confirm the 
hypothesis that in low-risk MDS, the emergence of auto-reactive T-cell 
clones could be responsible for BM hypoplasia. Moreover, the observed 
expansion of regulatory populations in the late disease stages, could 
represent an effective escape mechanism of the dysplastic clone/s to 
immune-mediated control of transformation, as described in other malignant 
diseases. 
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APPENDIX: Table I. HLA allele frequency distribution in PNH patients versus healthy controls 
  
HLA Genes Controls 
a
n (%) 
PNHa 
n (%) 
pb Odd Ratio (95%CI) 
A*02 119 (39.5) 23 (54.8) N.S 1.85         (0.96-3.54) 
A*0201 97 (32.2) 21 (52,5)˜ 0.03 2.32         (1,19-4,52) 
A*0205 22 (7.3) /   
A*0206 / /   
A*33 7 (2.3) 4 (9.5) N.S 4.42       (1.23-15.81) 
B*14 18 (5.9) 10 (23.8) 0.01 4.91       (2.08-11.55) 
B*1402 16 (5.3) 10 (23.8) 0.00064 5.56        (2.33-13.29) 
Cw*08 18 (5.9) 10 (23.8) 0.009       4.91        (2.08-11.55) 
Cw*0802 18 (5,9) 10 (23.8) 0.0014 4.91        (2.08-11.55) 
DRB1*15 30 (9.9) 8 (21.1) N.S        2.40        (1.01-5.73) 
DRB1*1501 16 (5.3) 8 (21.1) 0.006 4.75        (1.87-12.02) 
DRB1*01      33 (10.9) 12 (31.6) 0.01        3.74        (1.72-8.12)   
DRB1*0101 16 (5.3) 6 (15.7) 0.05        3.34        (1.22-9.14) 
DRB1*0102 17 (5.6) 5 (13.1) N.S.        2.57        (0.87-7.31) 
DRB1*07 82 (26.8) 4 (10.5) N.S        0.31       (0.10-0.91) 
HLA Haplotype     
B*1402, Cw*0802 16 (5.3) 10 (23.8) 0.00032   5.56       (2.33-13.29) 
A*33, B*1402, Cw*0802, DRB1*0102 2 (0.66) 4 (10.5) 0.001       17.58        (3.10-99.65) 
 
a data refer to 301 healthy controls and 42 or 38 PNH patients for HLA class I and class II respectively 
b p was calculated by Fisher's two tailed exact test; Bonferroni correction of p values was performed for allele 
association by considering specificities with a frequency >0.5% in Italians (i.e. 14 alleles at A locus with 3 specificities for 
A*02, 21 at B locus with 2 specificities for B*14, 13 at C locus with 2 specificities for Cw*08, 12 at DRB1 locus with 2 
specificities for DRB1*01 and 3 for DRB1*15) 
